Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.

Creative Commons License

Bilgiç Temel A., Bassorgun C. İ., Akman-Karakaş A., Alpsoy E., Uzun S.

Case reports in dermatology, cilt.9, ss.38-44, 2017 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Teknik Not
  • Cilt numarası: 9
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1159/000452828
  • Dergi Adı: Case reports in dermatology
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.38-44
  • Anahtar Kelimeler: Bullous pemphigoid, Omalizumab, Rituximab, Treatment, IGE AUTOANTIBODIES, AUTOIMMUNITY, THERAPY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FceRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reported to be effective in various autoimmune diseases, including autoimmune bullous dermatoses. A specific protocol for the use of rituximab to treat BP patients is not yet available. There are only small case series and case reports about the efficacy and safety of rituximab in BP. Here we present a young BP patient who responded well to rituximab therapy and was refractory to conventional and omalizumab therapies although he had elevated IgE levels and eosinophilia. Our case supports the knowledge about the effectiveness and safety of rituximab not only in pemphigus but also in BP. On the other hand, although it did not work in our case, omalizumab may be a potentially effective agent in some carefully selected patients with certain subtypes of BP. (C) 2017 The Author(s) Published by S. Karger AG, Basel